TransMedics Group (NASDAQ:TMDX) Earns Overweight Rating from Piper Sandler

TransMedics Group (NASDAQ:TMDX - Get Free Report)'s stock had its "overweight" rating restated by Piper Sandler in a report released on Tuesday, Benzinga reports. They currently have a $180.00 target price on the stock. Piper Sandler's target price would indicate a potential upside of 103.39% from the stock's previous close.

TMDX has been the subject of a number of other research reports. Canaccord Genuity Group cut their price target on TransMedics Group from $169.00 to $109.00 and set a "buy" rating for the company in a research note on Tuesday. Oppenheimer cut their target price on TransMedics Group from $200.00 to $125.00 and set an "outperform" rating on the stock in a research note on Tuesday. Needham & Company LLC cut their target price on TransMedics Group from $208.00 to $109.00 and set a "buy" rating on the stock in a research note on Tuesday. Robert W. Baird dropped their price objective on TransMedics Group from $200.00 to $150.00 and set an "outperform" rating on the stock in a research note on Tuesday. Finally, Stephens upped their price objective on TransMedics Group from $151.00 to $178.00 and gave the company an "overweight" rating in a research note on Friday, August 2nd. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $144.80.

TransMedics Group Stock Down 29.9 %

TMDX stock traded down $37.74 during mid-day trading on Tuesday, reaching $88.50. 11,660,088 shares of the company traded hands, compared to its average volume of 914,126. The stock has a market cap of $2.95 billion, a price-to-earnings ratio of 2,180.50 and a beta of 1.99. The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67. TransMedics Group has a fifty-two week low of $36.42 and a fifty-two week high of $177.37. The firm's 50 day moving average price is $147.58 and its 200 day moving average price is $140.19.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.28 by ($0.16). The company had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. TransMedics Group's revenue for the quarter was up 63.7% on a year-over-year basis. During the same quarter last year, the firm posted ($0.12) EPS. As a group, equities research analysts predict that TransMedics Group will post 1.22 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Waleed H. Hassanein sold 8,625 shares of the company's stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total value of $1,144,623.75. Following the completion of the transaction, the chief executive officer now directly owns 61,643 shares in the company, valued at approximately $8,180,642.53. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other TransMedics Group news, insider Tamer I. Khayal sold 2,958 shares of the company's stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $156.77, for a total transaction of $463,725.66. Following the completion of the sale, the insider now directly owns 20,843 shares in the company, valued at $3,267,557.11. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Waleed H. Hassanein sold 8,625 shares of the company's stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the sale, the chief executive officer now owns 61,643 shares of the company's stock, valued at approximately $8,180,642.53. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 64,205 shares of company stock worth $9,981,907. Corporate insiders own 7.00% of the company's stock.

Institutional Trading of TransMedics Group

Several institutional investors have recently added to or reduced their stakes in TMDX. Vanguard Group Inc. boosted its position in TransMedics Group by 2.8% during the fourth quarter. Vanguard Group Inc. now owns 1,865,115 shares of the company's stock valued at $147,214,000 after buying an additional 50,673 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in shares of TransMedics Group by 3.1% during the first quarter. Allspring Global Investments Holdings LLC now owns 730,010 shares of the company's stock worth $53,977,000 after purchasing an additional 21,737 shares during the period. Oak Ridge Investments LLC boosted its holdings in shares of TransMedics Group by 59.5% during the first quarter. Oak Ridge Investments LLC now owns 18,267 shares of the company's stock worth $1,351,000 after purchasing an additional 6,813 shares during the period. BNP Paribas Financial Markets boosted its holdings in shares of TransMedics Group by 35.1% during the first quarter. BNP Paribas Financial Markets now owns 17,390 shares of the company's stock worth $1,286,000 after purchasing an additional 4,518 shares during the period. Finally, Fidelis Capital Partners LLC purchased a new stake in shares of TransMedics Group during the first quarter worth about $35,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.